Our Work
Latham & Watkins Advises on Immunome’s US$400 Million Public Offering
December 17, 2025
Firm represents the underwriters in the offering by the biotechnology company.
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, has announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of US$21.50 per share. All of the shares are to be sold by Immunome.
Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by San Diego partner Matt Bush and counsel Anthony Gostanian, with associates Raul Gonzalez-Casarrubias, Sterling Swift, and Ivana Valdez.